AUTL Autolus Therapeutics ADS

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics to Participate in Upcoming Investor Conferences

LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences.

Jefferies Biotech on the Beach Summit

Management to host investor meetings

Date: March 11, 2025

Location: Miami, FL

Leerink Global Biopharma Conference

Fireside Chat Presentation

Date and time: March 12, 2025; 8:40am EDT / 12:40pm GMT

Location: Miami, FL

Presenter: Chief Executive Officer Dr. Christian Itin

A webcast of the fireside chat will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at . A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Autolus Therapeutics plc

Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit .

Contact:

Amanda Cray



Olivia Manser

8



EN
05/03/2025

Underlying

AUTLAutolus Therapeutics ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Autolus Therapeutics ADS

 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics to Report Second Quarter 2025 Financial Results a...

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 LONDON and GAITHERSBURG, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its second quarter 2025 financial results and operational highlights before open of U.S. markets on Tuesday, August 12, 2025. Management will host a conference call and webcast at 8:30am EDT/13:30pm BS...

July 24, 2025 1 EN
Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Wim Hoste
EXO EXOR N.V.
AUTL AUTOLUS THERAPEUTICS ADS
AKZA AKZO NOBEL N.V.
ECMPA EUROCOMMERCIAL PROPERTIES NV
07/22/25 July 22, 2025 1 EN
Michiel Declercq
  • Michiel Declercq
AUTL Autolus Therape...

Autolus Aucatzyl gains EC approval in r/r adult ALL

Autolus announced that the European Commission (EC) has granted marketing authorization for Aucatzyl (obe-cel, CD19 CAR-T) for the treatment of adults aged 26+ years with r/r B-ALL. Autolus will now evaluate market entry opportunities in the EU, which we expect to take place on a country-by-country basis – the company has previously indicated that the initial focus in the EU will be on Germany. More broadly, the US commercial launch in r/r adult ALL began in early 2025, and the first quarter of ...

AUTL AUTOLUS THERAPEUTICS ADS
07/22/25 July 22, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel...

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicityEC approval follows positive CHMP opinion, MHRA conditional marketing authorization and FDA approval LONDON and GAITHERSBURG, Md., July 21, 2025 (GLOBE NEWSWIRE) -- Autolus Therape...

July 21, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing ...

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 360,550 shares of its common stock to 60 employees pursuant to the Company’s 2025 Inducement Plan. The stock opti...

July 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch